Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus rituximab in relapsed/refractory lymphoma
NCT01996865Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2014
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of lenalidomide in follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), sponsored by Celgene Corporation. Started Apr 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01996865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01996865.